Ignite Creation Date:
2025-12-25 @ 2:33 AM
Ignite Modification Date:
2026-03-01 @ 12:07 PM
Study NCT ID:
NCT06513234
Status:
RECRUITING
Last Update Posted:
2024-07-22
First Post:
2024-07-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
IIT2024013
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None